Fulvestrant with or without anti‐HER2 therapy in patients in a postmenopausal hormonal state and with ER‐positive HER2‐positive advanced or metastatic breast cancer: A subgroup analysis of data from the Safari study (JBCRG‐C06)

BACKGROUND: The role of endocrine therapy in the treatment of patients in a postmenopausal hormonal state and with estrogen receptor (ER)‐positive, human epidermal growth factor receptor 2 (HER2)‐positive advanced or metastatic breast cancer (AMBC) is unclear. METHODS: We analyzed the data from 94 p...

Descripción completa

Detalles Bibliográficos
Autores principales: Masuyama, Misato, Masuda, Norikazu, Kawaguchi, Hidetoshi, Yamamoto, Yutaka, Saji, Shigehira, Nakayama, Takahiro, Aogi, Kenjiro, Anan, Keisei, Ohtani, Shoichiro, Sato, Nobuaki, Takano, Toshimi, Tokunaga, Eriko, Nakamura, Seigo, Hasegawa, Yoshie, Hattori, Masaya, Fujisawa, Tomomi, Morita, Satoshi, Yamaguchi, Miki, Yamashita, Toshinari, Yotsumoto, Daisuke, Toi, Masakazu, Ohno, Shinji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10523974/
https://www.ncbi.nlm.nih.gov/pubmed/37525895
http://dx.doi.org/10.1002/cam4.6390

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10523974/
https://www.ncbi.nlm.nih.gov/pubmed/37525895
http://dx.doi.org/10.1002/cam4.6390

Ejemplares similares